StockData
Basel Medical Group Ltd logo

Basel Medical Group Ltd (BMGL) company profile

BMGLNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends June 30
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 3/30
$0.32+0.02 (+7.34%)

Close on Nov 17, 2026Market cap $513.40KP/E –Yield –

About Basel Medical

Services-Offices & Clinics of Doctors of Medicine, SIC 8011

Basel Medical Group Ltd is a healthcare provider that specializes in orthopedic treatments and related medical services. The company focuses on the diagnosis, correction, prevention, and treatment of disorders affecting the musculoskeletal system, including bones, joints, muscles, ligaments, and tendons. Its operations encompass specialized orthopedic and sports clinics, physiotherapy services, and general medical care delivered through specialized practitioners, external medical professionals, and locum doctors. The organization primarily serves patients requiring orthopedic care, sports injury treatments, physiotherapy, and routine medical consultations.

The group operates medical clinics and facilities across Singapore, including locations in Orchard, Farrer Park, Novena, Suntec, Macpherson, Toa Payoh, Beach Road, Margaret Drive, and Tampines. While incorporated in the British Virgin Islands, Basel Medical Group Ltd maintains its principal executive offices and headquarters at Gleneagles Medical Centre in Singapore.

Summary of the business section of Basel Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
Basel Medical Group Ltd
Headquarters
Singapore, U0
Address
600 North Bridge Road, #12-02/03, Parkview Square 188778
Phone
(656) 291-9188
Employees
81, Jun 30, 2026
Industry
Services-Offices & Clinics of Doctors of Medicine
Incorporated in
D8
Fiscal year ends
June 30
Auditor
NLA DFK Assurance PAC, Singapore

Stock & identifiers

Ticker
BMGL
Exchange
Nasdaq
IPO date
Feb 25, 2025
Shares outstanding
2M, Jun 30, 2026
Filer category
Non-accelerated filer<br>Emerging growth company
Stock splits
1-for-12 reverse, Jun 22, 2026
SEC CIK
2004489
FIGI
BBG01PR70N34
Share class FIGI
BBG01PR70NY0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Boon Chye TanChief Commercial Officer, Director10,205,229
Alton Chun How NeoInterim CFO–
Jianing JN LuChief Financial Officer–
Darren Yen Feng ChhoaChief Executive Officer–
Xinwen YangDirector–
Frederick Shieh Ming HongDirector–
Kwek Yoon SoongDirector–
Keng Leong FungDirector10,205,229
Tony ChenDirector–
Paul D. FreudenthalerDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 25, 2025
Exchange
Nasdaq
First trading day
Feb 25, 2025
First-day close
$4.44
Lock-up ends (est.)
Aug 24, 2025

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We had 81 full-time employees as of June 30, 2025, and 74 full-time employees as of June 30, 2026.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?